低中危子宫内膜癌淋巴结评估三种策略的成本效果分析
该决策分析模型比较了前哨淋巴结示踪、术后危险因素评估和全淋巴结清扫在低中危子宫内膜样癌中的成本效果。前哨淋巴结示踪最具效果,相比危险因素评估的增量成本效果比最高为9637欧元/QALY,低于20000欧元支付阈值,且相比全淋巴结清扫具优势。敏感性分析显示结果稳健。
要点
- 前哨淋巴结示踪是低中危子宫内膜癌淋巴结评估中最具成本效果的策略。
- 相比危险因素评估,前哨淋巴结示踪增量成本效果比最高为9637欧元/QALY。
- 前哨淋巴结示踪相比全淋巴结清扫更具效果且成本更低(占优)。
核心结论
- 前哨淋巴结示踪是指导低中危子宫内膜样癌辅助治疗需求的最具成本效果的策略。
研究设计与样本
- 决策分析模型,从医疗保健视角比较三种淋巴结评估策略,输入数据来自系统文献检索和专家意见,效果指标为QALYs。
主要发现
- 基础案例分析显示前哨淋巴结示踪是最有效的策略。
- 相比危险因素评估,前哨淋巴结示踪成本更高,但增量成本效果比最高为9637欧元/QALY,低于20000欧元支付阈值。
- 前哨淋巴结示踪相比淋巴结清扫占优,即更有效且成本更低。
- 敏感性分析显示模型结果对输入值变化稳健。
- 在20000欧元支付阈值下,前哨淋巴结示踪在至少74.3%的迭代中保持成本效果。
关键数值与推荐
- 增量成本效果比最高为9637欧元/QALY(前哨淋巴结示踪 vs 危险因素评估)。
- 支付意愿阈值为20000欧元。
- 前哨淋巴结示踪在至少74.3%的迭代中具有成本效果(支付阈值20000欧元)。
临床怎么用
- 对于低中危子宫内膜样癌患者,可优先考虑前哨淋巴结示踪以指导辅助治疗决策,兼具成本效果优势。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the cost-effectiveness of sentinel lymph node mapping compared to risk factor assessment and routine full lymph node dissection for the assessment of lymph nodes in patients with low- and intermediate-risk endometrioid endometrial cancer. METHODS: A decision-analytic model was designed to compare three lymph node assessment strategies in terms of costs and effects: 1) sentinel lymph node mapping; 2) post-operative risk factor assessment (adjuvant therapy based on clinical and histological risk factors); 3) full lymph node dissection. Input data were derived from systematic literature searches and expert opinion. QALYs were used as measure of effectiveness. The model was built from a healthcare perspective and the impact of uncertainty was assessed with sensitivity analyses. RESULTS: Base-case analysis showed that sentinel lymph node mapping was the most effective strategy for lymph node assessment in patients with low- and intermediate-risk endometrial cancer. Compared to risk factor assessment it was more costly, but the incremental cost effectiveness ratio stayed below a willingness-to-pay threshold of €20,000 with a maximum of €9637/QALY. Sentinel lymph node mapping was dominant compared to lymph node dissection since it was more effective and less costly. Sensitivity analyses showed that the outcome of the model was robust to changes in input values. With a willingness-to-pay threshold of €20,000 sentinel lymph node mapping remained cost-effective in at least 74.3% of the iterations. CONCLUSION: Sentinel lymph node mapping is the most cost-effective strategy to guide the need for adjuvant therapy in patients with low and intermediate risk endometrioid endometrial cancer.
引用
- Burg LC, Vermeulen RJ, Bekkers RLM, et al. A cost-effectiveness analysis of three approaches for lymph node assessment in patients with low- and intermediate-risk endometrial cancer. Gynecol Oncol. 2021. PMID: 33581847. doi:10.1016/j.ygyno.2021.01.035
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。